CLINICAL TRIALS PROFILE FOR BIAXIN XL

All Clinical Trials for BIAXIN XL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	Mayo Clinic	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Celgene Corporation	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Weill Medical College of Cornell University	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.

Clinical Trial Conditions for BIAXIN XL

Condition Name

Condition Name for BIAXIN XL
Intervention	Trials
Healthy	13
Multiple Myeloma	10
Idiopathic Hypersomnia	2
Infection	2

Condition MeSH

Condition MeSH for BIAXIN XL
Intervention	Trials
Neoplasms, Plasma Cell	15
Multiple Myeloma	15
Pneumonia	3
Narcolepsy	2

Clinical Trial Locations for BIAXIN XL

Trials by Country

Trials by Country for BIAXIN XL
Location	Trials
United States	97
China	24
Canada	19
Korea, Republic of	4
India	3

Trials by US State

Trials by US State for BIAXIN XL
Location	Trials
New York	9
Arizona	7
Missouri	6
Washington	6
Texas	5

Clinical Trial Progress for BIAXIN XL

Clinical Trial Phase

Clinical Trial Phase for BIAXIN XL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for BIAXIN XL
Clinical Trial Phase	Trials
Completed	37
Active, not recruiting	4
Recruiting	4

Clinical Trial Sponsors for BIAXIN XL

Sponsor Name

Sponsor Name for BIAXIN XL
Sponsor	Trials
Abbott	6
Weill Medical College of Cornell University	5
Ranbaxy Laboratories Limited	5

Sponsor Type

Sponsor Type for BIAXIN XL
Sponsor	Trials
Industry	43
Other	40
NIH	6